Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Cited by (1,000)

Items 401–500 of 1,000

1. Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma
   Wilson I. Gonsalves, Kelly Nicole Godby, Shaji Kunnathu Kumar, Luciano J. Costa · 2015 · American Journal of Hematology
2. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients
   Mauricette Michallet, Mohamad Sobh, Jean El Cheikh, Stéphane Morisset, Anne Sîrvent, Oumédaly Reman, Jérôme Cornillon, Reza Tabrizi, Noel Jean Milpied, Jean‐Luc Harousseau et al. · 2013 · Experimental Hematology
3. Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective
   Kai Hübel, Javier de la Rubia, Nabih Azar, Paolo Corradini · 2014 · European Journal Of Haematology
4. Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QT c Intervals in the Thorough QT c Study Conducted in Healthy Men
   Nianhang Chen, Ying Ye, Liangang Liu, Josephine F. Reyes, Mahmoud S. Assaf, Claudia Kasserra, Simon Yuji Zhou, Maria Palmisano · 2013 · Basic & Clinical Pharmacology & Toxicology
5. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
   Aristoteles A. N. Giagounidis · 2012 · Seminars in Hematology
6. Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
   Sophie Maïga, Patricia Gomez‐Bougie, Stéphanie Bonnaud, Catherine Gratas, Philippe Moreau, Steven Le Gouill, Catherine Pellat‐Deceunynck, Martine Amiot · 2013 · British Journal of Cancer
7. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis
   Emmanuel Clave, Corinne Douay, Téreza Coman, Marc Busson, Caroline Bompoint, Hélène Moins‐Teisserenc, Salomé Glauzy, Maryvonnick Carmagnat, Norbert Claude Gorin, Antoine Toubert et al. · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
8. A facile and efficient method for the synthesis of N -substituted isoindolin-1-one derivatives under Pd(OAc) 2 /HCOOH system
   Yang Zhou, Ping Chen, Xue Lv, Junxing Niu, Yingying Wang, Min Lei, Lihong Hu · 2017 · Tetrahedron Letters
9. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
   Eirini Katodritou, Marie‐Christine Kyrtsonis, Sosana Delimpasi, Despoina S Kyriakou, Argiris S. Symeonidis, Emmanouil Spanoudakis, Georgios Vasilopoulos, Αchilles Anagnostopoulos, Anna Kioumi, Panagiotis Zikos et al. · 2018 · Annals of Hematology
10. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
    M Hasib Sidiqi, Mohammed A. Aljama, Irbaz Bin Riaz, Angela A. Dispenzieri, Eli Muchtar, Francis K. Buadi, Rahma M. Warsame, Martha Q. Lacy, David Dingli, Nelson Leung et al. · 2018 · Blood Cancer Journal
11. The pharmacologic management of multiple myeloma in older adults
    Jessica L. Dempsey, Andrew C. Johns, Ashley Elizabeth Rosko, Hillard Michael Lazarus · 2019 · Expert Opinion on Pharmacotherapy
12. Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time
    Amanda Putri Rahmadian, Seanthel Delos Santos, Shruti Parshad, Louis Everest, Matthew C. Cheung, Kelvin Chan · 2020 · Journal of the National Comprehensive Cancer Network
13. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
    Samantha Pozzi, Alessia Bari, Martin Pecherstorfer, Sonia Vallet · 2021 · Cancers
14. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial
    Steve Schey, Sarah Brown, Avie‐Lee Tillotson, Kwee Yong, C. D. Williams, Faith E. Davies, Gareth John Morgan, Jamie D. Cavenagh, Gordon Cook, Mark A. Cook et al. · 2015 · British Journal of Haematology
15. A Case Report of Chronic Myelogenous Leukemia in a Patient With Multiple Myeloma and a Review of the Literature
    Loheetha Ragupathi, Vesna Najfeld, Ajai Chari, Bruce E. Petersen, Sundar Jagannath, John O Mascarenhas · 2012 · Clinical Lymphoma Myeloma & Leukemia
16. Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
    Alessandro Gozzetti, Donatella Raspadori, Francesca Bacchiarri, Anna Sicuranza, Paola Pacelli, Ilaria Ferrigno, Dania Tocci, Monica Bocchia · 2020 · Journal of Personalized Medicine
17. Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
    Stephan Bohl, Laura Katharina Schmalbrock, Imke Bauhuf, Tatjana Meyer, Anna Dolnik, Martin Szyska, Tamara J. Blätte, Sarah Knödler, Linda Röhner, Denise Miller et al. · 2021 · Blood Advances
18. Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques
    Noa Biran, Scott A. Ely, Ajai Chari · 2014 · Current Hematologic Malignancy Reports
19. Phase I‐ II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
    Donna Ellen Reece, Esther Masih‐Khan, Eshetu G. Atenafu, Victor Hugo Jimenez-Zepeda, Peter Anglin, Christine I. Chen, Vishal Kukreti, Joseph R Mikhael, Suzanne Trudel · 2014 · British Journal of Haematology
20. Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
    Wirk · 2013 · Journal of Clinical Medicine Research
21. How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events
    María‐Victoria Mateos · 2012 · Leukemia Research
22. Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes ( C row– F ukase) syndrome: Diagnostic criteria and treatment perspectives
    Sonoko Misawa, Satoshi Kuwabara · 2013 · Clinical and Experimental Neuroimmunology
23. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
    Dharshan Sivaraj, Wendi Bacon, Gwynn Douglas Long, David Alan Rizzieri, Michael E Horwitz, Keith M. Sullivan, Yubin Kang, Z. Li, Nelson Jen An Chao, Cristina Gasparetto · 2017 · Bone Marrow Transplantation
24. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee
    Sarah A. Holstein, Hervé Avet‐Loiseau, Theresa Hahn, Christine M. Ho, Jens G. Lohr, Nikhil C. Munshi, Bruno Paiva, Marcelo C. Pasquini, Joseph Dennis Tario, Saad Z. Usmani et al. · 2017 · Transplantation and Cellular Therapy
25. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
    Jennifer J. Huang, Sharon E. Phillips, Michael Thomas Byrne, Wichai Chinratanalab, Brian G. Engelhardt, Stacey Ann Goodman, Shelton Lacy Harrell, Madan Jagasia, Adetola A. Kassim, Kyle T. Rawling et al. · 2018 · Bone Marrow Transplantation
26. Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
    Catherine Thiéblemont, Susannah Howlett, Olivier Casasnovas, Nicolas Mounier, Aurore Perrot, Franck Morschhauser, Christophe Fruchart, Nicolas Daguindau, Koen Van Eygen, Lucie Obéric et al. · 2019 · British Journal of Haematology
27. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
    Francesca Gay, Roberto Mina, Rossella Troia, Sara Bringhen · 2013 · Expert Opinion on Drug Metabolism & Toxicology
28. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma
    Ricardo García‐Muñoz, Diego Robles de Castro, Aura Muñoz, Pilar Rabasa · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
29. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies
    Machaon Bonafede, Akshara Richhariya, Qian Cai, Neil C. Josephson, Donna McMorrow, Phillip M. Garfin, Miguel‐Angel Perales · 2017 · Journal of Medical Economics
30. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes
    Bei Hu, Peter F. Thall, Denái R. Milton, Koji Sasaki, Qaiser Bashir, Nina D. Shah, Krina K. Patel, Uday Popat, Chitra M. Hosing, Yago L. Nieto et al. · 2018 · Leukemia & lymphoma/Leukemia and lymphoma
31. Multiple myeloma: a model for scientific and clinical progress
    Jesús F. San Miguel · 2014 · Hematology
32. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
    Michael M. Boyiadzis, Michael Bishop, Rafat Abonour, Kenneth Carl Anderson, Stephen Maxted Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen van Besien, Peter Leif Bergsagel et al. · 2016 · Journal for ImmunoTherapy of Cancer
33. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
    John R Jones, David Allan Cairns, Tom Menzies, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin Kaiser, Catherine Olivier et al. · 2023 · EClinicalMedicine
34. Role of Immune Cells and Immunotherapy in Multiple Myeloma
    Vijay Radhakrishnan, Upendarrao Golla, Avinash Kundadka Kudva · 2024 · Life
35. Renal transplant in plasma cell dyscrasias with lenalidomide treatment after autologous stem cell transplantation
    Ana Sánchez Quintana, Pablo Ríos Rull, Joaquín Breña Atienza, Cristina Notario · 2013 · Nephrology
36. Antiproliferative and antibacterial activity of some glutarimide derivatives
    Jelena B. Popović‐Djordjević, Anita S. Klaus, Željko S. Žižak, Ivana Z. Matić, Branko J. Drakulić · 2015 · Journal of Enzyme Inhibition and Medicinal Chemistry
37. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance
    Dmitriy Zamarin, Sean M. Devlin, Maria E. Arcila, Heather Jolie Landau, Alexander M. Lesokhin, Nikoletta K. Lendvai, David J. Chung, Danielle Chimento, Jonathan Weltz, D Babu et al. · 2013 · Leukemia
38. Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation
    Imran Ahmad, Richard LeBlanc, Sandra Cohen, Silvy Lachance, Thomas L. Kiss, Guy Sauvageau, D-C Roy, Lambert Busque, Jean‐Sébastien Delisle, Nadia M. Bambace et al. · 2015 · Bone Marrow Transplantation
39. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy
    Wilson I. Gonsalves, S. Vincent Rajkumar, Morie Abraham Gertz, Angela A. Dispenzieri, Martha Q. Lacy, Francis K. Buadi, David Dingli, Ronald S. Go, Nelson Leung, Prashant Kapoor et al. · 2016 · Bone Marrow Transplantation
40. Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
    Bernard D. Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy · 2016 · Transplantation and Cellular Therapy
41. Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report
    Vighnesh Walavalkar, Deborah Adey, Zoltan G. Laszik, Kuang‐Yu Jen · 2018 · Transplantation Proceedings
42. Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy
    Sophia Danhof, Susanne Strifler, Dorothea Hose, Klaus Martin Kortüm, Max Bittrich, Jochen Hefner, Hermann Einsele, Stefan Tobias Knop, Martin Schreder · 2018 · Journal of Cancer Research and Clinical Oncology
43. The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
    Matthew Ho, Saurabh Zanwar, Prashant Kapoor, Morie Abraham Gertz, Martha Q. Lacy, Angela A. Dispenzieri, Suzanne R. Hayman, David Dingli, Francis K. Baudi, Eli Muchtar et al. · 2021 · Blood Cancer Journal
44. The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation
    Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network · 2016 · Transplantation and Cellular Therapy
45. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
    H. Ludwig, Michel Delforge, Thierry T.F. Facon, Hermann Einsele, Francesca Gay, Philippe Moreau, Hervé Avet‐Loiseau, Mario Boccadoro, Roman Hájek, Mohamad Mohty et al. · 2017 · Leukemia
46. Lenalidomide in Multiple Myeloma—A Practice Guideline
    C. Chen, Fulvia G. Baldassarre, Sindu Mary Kanjeekal, Jordan A. Herst, Lisa K. Hicks, Matthew C. Cheung · 2013 · Current Oncology
47. Hematopoietic Stem Cell Transplantation
    Annie Im, Steven Zivko Pavletic · 2020 · Elsevier eBooks
48. The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma
    Mark Sellin, Stephanie A Berg, Patrick Alan Hagen, Jiwang Zhang · 2022 · Translational Oncology
49. Elranatamab: a new promising BispAb in multiple myeloma treatment
    Sebastian Grosicki, Martyna Bednarczyk, Karolina Kociszewska · 2023 · Expert Review of Anticancer Therapy
50. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma
    Oren Pasvolsky, Sassine Ghanem, Denái R. Milton, Adeel Masood, Mark R. Tanner, Qaiser Bashir, Samer Ali Srour, Neeraj Saini, Paul Y. Lin, Jeremy Ramdial et al. · 2023 · Transplantation and Cellular Therapy
51. Small molecule-regulated switches to provide functional control of CAR T cells within the patient
    Charlotte U. Zajc, Elise Sylvander, Manfred Lehner, Michael W. Traxlmayr · 2024 · Expert Opinion on Biological Therapy
52. Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
    Xueshi Ye, Jinwen Huang, Qin Pan, Wanli Li · 2013 · PLoS ONE
53. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients
    Philip L. McCarthy, Hermann Einsele, Michel Attal, Sergio Giralt · 2014 · Expert Review of Hematology
54. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma
    Taiga Nishihori, Jose Leonel Ochoa-Bayona, J Kim, Joseph Pidala, Kenneth H. Shain, Rachid Baz, Daniel M. Sullivan, Heather Jim, Claudio Anasetti, Melissa Alsina · 2013 · Bone Marrow Transplantation
55. Maintenance Therapy for Multiple Myeloma
    Philip L. McCarthy, Antonio Pierangelo Palumbo · 2014 · Hematology/Oncology Clinics of North America
56. Biology and Treatment of Myeloma
    Annamaria Brioli, Lorenzo Melchor, Brian A. Walker, Faith E. Davies, Gareth John Morgan · 2014 · Clinical Lymphoma Myeloma & Leukemia
57. Role of stem cell transplant and maintenance therapy in plasma cell disorders
    Philip L. McCarthy, Sarah A. Holstein · 2016 · Hematology
58. Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004–2014
    Anita D’Souza, M-J Zhang, J Huang, M Fei, Marcelo C. Pasquini, Mehdi Hamadani, Parameswaran Hari · 2017 · Leukemia
59. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure
    Ahmad Alhuraiji, Kiran Naqvi, Yang O. Huh, Coty Ho, Srđan Verstovšek, Prithviraj Bose · 2017 · Clinical Case Reports
60. Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia
    Taro Tochigi, Toshihiro Miyamoto, Kiwamu Hatakeyama, Teppei Sakoda, Daisuke Ishihara, Hidetoshi Irifune, Takahiro Shima, Koji Kato, Takahiro Maeda, Takumi Ito et al. · 2020 · Blood
61. Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
    Kelly L. Schoenbeck, Tanya Marya Wildes · 2020 · Clinical Interventions in Aging
62. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database
    Hannah Marie Cherniawsky, Vishal Kukreti, Donna Ellen Reece, Esther Masih‐Khan, Arleigh B. Robertson McCurdy, Victor Hugo Jimenez-Zepeda, Michaël Sébag, Kevin Song, Darrell J. White, Julie Stakiw et al. · 2020 · Haematologica
63. Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma
    Radowan A. Elnair, Sarah A. Holstein · 2021 · Drugs
64. Current Treatment Approaches to Newly Diagnosed Multiple Myeloma
    Susanne Ghandili, Katja Christina Weisel, Carsten Bokemeyer, Lisa Beatrice Leypoldt · 2021 · Oncology Research and Treatment
65. Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
    Jordan S. Nunnelee, Francesca Cottini, Qiuhong Zhao, Muhammad Salman Faisal, Patrick Elder, Ashley Elizabeth Rosko, Naresh Bumma, Abdullah Khan, Srinivas S. Devarakonda, Don M. Benson et al. · 2022 · Cancers
66. Bortezomib for the treatment of multiple myeloma
    Sebastian Grosicki, Agnieszka Barchnicka, Artur J. Jurczyszyn, Anida Grosicka · 2014 · Expert Review of Hematology
67. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low‐dose cyclophosphamide: a randomized comparison
    Jaakko Valtola, Raija Helena Silvennoinen, Antti Ropponen, Timo Siitonen, Marjaana Säily, Marja Sankelo, Venla Terävä, Mervi Putkonen, Taru Kuittinen, Jukka Pelkonen et al. · 2016 · Transfusion
68. Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation
    Zachariah Michael DeFilipp, Yi‐Bin Chen · 2016 · Transplantation and Cellular Therapy
69. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
    Firoozeh Sahebi, Simona Iacobelli, Giulia Sbianchi, Linda Köster, Didier Blaise, Peter Pal Remenyi, Nigel H. Russell, Per T Ljungman, Guido Kobbe, Jane F. Apperley et al. · 2018 · Transplantation and Cellular Therapy
70. Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
    Hartmut Goldschmidt, Meletios Athanasios Dimopoulos, S. Vincent Rajkumar, Katja Christina Weisel, Philippe Moreau, Wee Joo Chng, Gábor Mikala, Michèle Cavo, Karthik Ramasamy, Kaveri Suryanarayan et al. · 2020 · Leukemia
71. Treatment trade‐offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies
    Brian Leslie Burnette, Angela A. Dispenzieri, Shaji Kunnathu Kumar, Ann M. Harris, Jeff A. Sloan, Jon Charles Tilburt, Robert A. Kyle, S. Vincent Rajkumar · 2013 · Cancer
72. Allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Guenther Koehne, Sergio Giralt · 2012 · Current Opinion in Oncology
73. Emerging biological insights and novel treatment strategies in multiple myeloma
    Massimo Gentile, Anna Grazia Recchia, Carla Mazzone, Fortunato Morabito · 2012 · Expert Opinion on Emerging Drugs
74. The risk of secondary primary malignancies after therapy for multiple myeloma
    Nuchanan Areethamsirikul, Donna Ellen Reece · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
75. Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features
    Abdullah Khan, Jameel Muzaffar, Hemant S. Murthy, John R. Wingard, Jan S. Moreb · 2018 · Case Reports in Hematology
76. Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma
    Isabel G. Amsler, Barbara Jeker, Behrouz Mansouri Taleghani, Ulrike Bacher, Daniel C. Betticher, Thomas Egger, Thilo Zander, Jean-Marc Lüthi, Urban Novak, Thomas Pabst · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
77. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma
    Susan Bal, Allison Weaver, Robert Frank Cornell, Luciano J. Costa · 2019 · British Journal of Haematology
78. Future Directions in Maintenance Therapy in Multiple Myeloma
    Sarah A. Holstein, Vera Jean Suman, Jens Hillengass, Philip L. McCarthy · 2021 · Journal of Clinical Medicine
79. Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation
    Taiga Nishihori, Sarah M. Abu Kar, Rachid Baz, Melissa Alsina, Jean‐Luc Harousseau, Mohamed A. Kharfan‐Dabaja · 2013 · Transplantation and Cellular Therapy
80. An old drug with a new future: bendamustine in multiple myeloma
    Massimo Gentile, Anna Grazia Recchia, Carla Mazzone, Ernesto Vigna, Massimo Vincenzo Martino, Lucio Morabito, Eugenio Lucia, Sabrina Bossio, Laura De Stefano, Teresa Granata et al. · 2013 · Expert Opinion on Pharmacotherapy
81. Evolving therapeutic paradigms for multiple myeloma: back to the future
    Benjamin M. Cherry, Neha Korde, Mary Kwok, Mark J. Roschewski, Ola Landgren · 2012 · Leukemia & lymphoma/Leukemia and lymphoma
82. New pharmacotherapy options for multiple myeloma
    Roberto Mina, Chiara Cerrato, Annalisa Bernardini, Elena Aghemo, Antonio Pierangelo Palumbo · 2015 · Expert Opinion on Pharmacotherapy
83. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft
    U Gössi, Barbara Jeker, Behrouz Mansouri Taleghani, Ulrike Bacher, Urban Novak, Daniel C. Betticher, Thomas Egger, Thilo Zander, Thomas Pabst · 2018 · Hematological Oncology
84. Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents
    Yi‐Bin Chen, Philip L. McCarthy, Theresa Hahn, Sarah A. Holstein, Masumi Ueda, Nicolaus Martin Kröger, Michael Russell Bishop, Marcos J. G. De Lima · 2018 · Bone Marrow Transplantation
85. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
    Mattia D’Agostino, Lorenzo De Paoli, Concetta Conticello, Massimo Offidani, Roberto Ria, Maria Teresa Petrucci, Stefano Spada, Magda Marcatti, Lucio Catalano, Milena Gilestro et al. · 2018 · Critical Reviews in Oncology/Hematology
86. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group
    Sini Luoma, Pekka M. Anttila, Marjaana Säily, Tuija Lundán, Jouni Heiskanen, Timo Siitonen, Sakari Kakko, Mervi Putkonen, Hanna Ollikainen, Venla Terävä et al. · 2019 · Annals of Hematology
87. Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation
    Liana Nikolaenko, Saurabh Chhabra, Noa Biran, Arnab Chowdhury, Parameswaran Hari, Amrita Y. Krishnan, Joshua Ryan Richter · 2020 · Clinical Lymphoma Myeloma & Leukemia
88. NCCN Guidelines Update for Multiple Myeloma
    Kenneth Carl Anderson · 2016 · Journal of the National Comprehensive Cancer Network
89. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review
    Ryan B. Sinit, Dick G. Hwang, Prakash Vishnu, Jess F. Peterson, David Michael Aboulafia · 2019 · BMC Cancer
90. The emerging role of targeted protein degradation to treat and study cancer
    Maximillian Hugo Brodermann, Elizabeth K Henderson, Rob S. Sellar · 2024 · The Journal of Pathology
91. Novel immunomodulatory compounds in multiple myeloma
    Neeraj Y. Saini, Anuj Kumar Mahindra · 2012 · Expert Opinion on Investigational Drugs
92. Lenalidomide maintenance—perils of a premature denouement
    S. Vincent Rajkumar · 2012 · Nature Reviews Clinical Oncology
93. Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma
    Annamaria Brioli, Martin Kaiser, Charlotte Pawlyn, Ping Wu, Walter Martin Gregory, Roger G. Owen, Fiona M. Ross, Graham Hunter Jackson, Michèle Cavo, Faith E. Davies et al. · 2012 · Leukemia & lymphoma/Leukemia and lymphoma
94. All transplantation-eligible patients with myeloma should receive ASCT in first response
    Philippe Moreau, Michel Attal · 2014 · Hematology
95. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
    Taiga Nishihori, Jinming Song, Kenneth H. Shain · 2016 · Current Hematologic Malignancy Reports
96. Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
    Pellegrino Musto, Vittorio Montefusco · 2016 · Expert Review of Hematology
97. Therapy-related myeloid neoplasms after treatment for plasma-cell disorders
    Alfred Chung, Michaela Liedtke · 2019 · Best Practice & Research Clinical Haematology
98. Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results
    Rita Fazzi, Iacopo Petrini, Nicola Giuliani, Riccardo Morganti, Giovanni Carulli, Benedetta Dalla Palma, Laura Notarfranchi, Sara Galimberti, Gabriele Buda · 2021 · Frontiers in Immunology
99. PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
    Chenggong Li, Yan Sun, Jing Wang, Lu Tang, Huiwen Jiang, Tao Guo, Lin Liu, Yaohui Wu, Lisha Ai, Linghui Xia et al. · 2021 · Frontiers in Immunology
100. Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy
     Flavia Stella, Estela Pedrazzini, Mara Agazzoni, Oscar Ballester, Irma Rosa Slavutsky · 2015 · Cancer Investigation